0 results available. Select is focused ,type to refine list, press Down to open the menu,
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable sm...
The following section summarizes insights on Durect Corporation's Levered FCF CAGR (5y):
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Levered FCF CAGR (5y) in the growth category include:
Five-year compound annual growth rate in levered free cash flow.
The chart above depicts the distribution of levered fcf cagr (5y) for companies operating in the Healthcare sector in the Developed economic region. Over 420 companies were considered in this analysis, and 409 had meaningful values. The average levered fcf cagr (5y) of companies in the sector is 12.4% with a standard deviation of 22.0%.
Durect Corporation's Levered FCF CAGR (5y) of NM- ranks in the - percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 427 |
| Included Constituents | 409 |
| Min | -37.4% |
| Max | 100.5% |
| Median | 8.6% |
| Mean | 12.4% |
| Standard Deviation | 22.0% |
You can find companies with similar levered fcf cagr (5y) using this stock screener.